Health care stocks:
Healthcare shares are mixed in pre-market. Sarepta Therapeutics
) is down more than 10% after making sharp gains in pre-market
trading, adding as much as 17% before slumping, after
) and Prosensa (
) said their phase III clinical study for their Duchenne Muscular
Dystrophy drug didn't meet the primary endpoint.
In the GSK and Prosensa study, the drisapersen drug didn't
result in statistical significant improvement in the walking test.
GSK is up 0.5% at $50.50.
And, in other healthcare news, GlaxoSmithKline and partner
Theravance, Inc. (
) announced that the Japanese Ministry of Health, Labour and
Welfare has approved RELVAR ELLIPTA for the treatment of bronchial
Under the terms of the 2002 LABA collaboration agreement,
Theravance is obligated to make a milestone payment of $10 million
to GSK following, Japanese Ministry of Health approval of Relvar
Ellipta. THRX is flat at $41.20.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.